An open-label study changing generic clozapine formulation to FazaClo® (clozapine, USP) orally disintegrating tablets in stable patients with schizophrenia or schizoaffective disorder

被引：0
|
作者：
Lindenmayer, Jean-Pierre [1 ,2 ,3 ]
Kaushik, Sashank [2 ,3 ]
Khan, Anzalee [2 ,3 ]
Kaushik, Saurabh [2 ,3 ]
机构：
[1] NYU, Sch Med, New York, NY USA
[2] Nathan S Kline Inst Psychiat Res, Psychopharmacol Res Program, Orangeburg, NY 10962 USA
[3] Manhattan Psychiat Ctr, Psychopharmacol Res, Wards Isl, NY USA
来源：
BIOLOGICAL PSYCHIATRY | 2008年 / 63卷 / 07期
关键词：
D O I：
暂无
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
906
引用
收藏
页码：287S / 287S
页数：1
相关论文
共 50 条
  • [11] Sensory evaluation of edoxaban orally disintegrating tablets: an open-label interventional study (secondary publication)
    Yamashita, Takeshi
    Hagii, Joji
    Morishima, Yoshiyuki
    Akasaka, Takaaki
    Matsumoto, Takuyuki
    Kimura, Tetsuya
    THROMBOSIS JOURNAL, 2019, 17 (1)
  • [12] Sensory evaluation of edoxaban orally disintegrating tablets: an open-label interventional study (secondary publication)
    Takeshi Yamashita
    Joji Hagii
    Yoshiyuki Morishima
    Takaaki Akasaka
    Takuyuki Matsumoto
    Tetsuya Kimura
    Thrombosis Journal, 17
  • [13] CHQ and CGAS in an open-label study of ziprasidone in pediatric patients with bipolar disorder, schizophrenia, or schizoaffective disorder
    DelBello, Melissa
    Stewart, Michelle
    Versavel, Mark
    Keller, David
    Miceli, Jeffrey
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2006, 16 (06) : 662 - 662
  • [14] Do formulation switches exacerbate existing medical illness? Results of an open-label transition to orally disintegrating risperidone tablets
    Chue, Pierre
    Prinzo, Rosanna S.
    Binder, Carin E.
    HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2007, 22 (05) : 307 - 314
  • [15] An open-label naturalistic study: Mirtazapine orally disintegrating tablets treatment for depression in heroin-addicts
    Shao, C.
    Zhu, S.
    Wang, Z.
    Shi, S.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2014, 17 : 128 - 129
  • [16] Reboxetine add-on to clozapine in treatment of negative symptoms of schizophrenia: a preliminary open-label study
    Quattrone, D.
    Bruno, A.
    Mico, U.
    Pandolfo, G.
    Scimeca, G.
    Muscatello, M. R.
    Zoccali, R.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2013, 23 : S469 - S469
  • [17] Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder - Randomised, controlled, open-label study
    Keks, Nicholas A.
    Ingham, Michael
    Khan, Akbar
    Karcher, Keith
    BRITISH JOURNAL OF PSYCHIATRY, 2007, 191 : 131 - 139
  • [18] THE OPTIMISE STUDY: AMISULPRIDE AND OLANZAPINE FOLLOWED BY OPEN-LABEL TREATMENT WITH CLOZAPINE IN FIRST-EPISODE SCHIZOPHRENIA
    Arango, Celso
    SCHIZOPHRENIA BULLETIN, 2019, 45 : S115 - S115
  • [19] Use of Paliperidone in Elderly Patients With Schizophrenia and Schizoaffective Disorder A Prospective Open-Label Short-Term Pilot Study
    Madhusoodanan, Subramoniam
    Brenner, Ronald
    Serper, Mark R.
    Adelsky, Margarita
    Adler, David N.
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2011, 31 (03) : 380 - 382
  • [20] Reboxetine Adjuvant Therapy in Patients With Schizophrenia Showing a Suboptimal Response to Clozapine A 12-Week, Open-Label, Pilot Study
    Bruno, Antonio
    Zoccali, Rocco
    Bellinghieri, Paolo Micali
    Pandolfo, Gianluca
    De Fazio, Pasquale
    Spina, Edoardo
    Muscatello, Maria Rosaria A.
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2014, 34 (05) : 620 - 623
12345